Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

December 9, 2021

Study Completion Date

February 6, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Disulfiram

Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.

DRUG

Copper Gluconate

Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cantex Pharmaceuticals

INDUSTRY

lead

University of Utah

OTHER